Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2015

01-10-2015 | Letter to the Editor

RE: Bartula I, Sherman KA: Development and validation of the Female Sexual Function Index adaptation for breast cancer patients (FSFI-BC)

Authors: Vincenzo Puppo, Giulia Puppo

Published in: Breast Cancer Research and Treatment | Issue 3/2015

Login to get access

Excerpt

Bartula and Sherman stated “This study determined the reliability, validity, and acceptability of a breast cancer-specific adaptation of the Female Sexual Function Index” [1]. …
Literature
1.
Bartula I, Sherman KA (2015) Development and validation of the Female Sexual Function Index adaptation for breast cancer patients (FSFI-BC). Breast Cancer Res Treat 152:477–488CrossRefPubMed
2.
Forbes MK, Baillie AJ, Schniering CA (2014) Critical flaws in the female sexual function index and the international index of erectile function. J Sex Res 51:485–491CrossRefPubMed
3.
Puppo V (2013) Anatomy and physiology of the clitoris, vestibular bulbs, and labia minora with a review of the female orgasm and the prevention of female sexual dysfunction. Clin Anat 26:134–152CrossRefPubMed
Metadata
Title
RE: Bartula I, Sherman KA: Development and validation of the Female Sexual Function Index adaptation for breast cancer patients (FSFI-BC)
Authors
Vincenzo Puppo
Giulia Puppo
Publication date
01-10-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3574-1

Other articles of this Issue 3/2015

Breast Cancer Research and Treatment 3/2015 Go to the issue

Epidemiology

Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging

Epidemiology

The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis

Clinical trial

The clinical significance of internal mammary lymph node (IMLN) biopsy during autologous reconstruction in breast cancer patients

Epidemiology

Identifying patterns of breast cancer care provided at high-volume hospitals: a classification and regression tree analysis

Epidemiology

Breast cancer screening utilization and understanding of current guidelines among rural U.S. women with private insurance

Clinical trial

Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits